Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

by admin | May 22, 2020 | Research Materials on Influenza and Coronaviral Prevention and Treatment